Due to the difficulty in pharmacologically targeting MYCN protein, along with the independent role of MYCN mRNA in regulating NB progression, targeting of MYCN mRNA by small-molecule inhibitors may represent an attractive strategy for therapy of MYCN-amplified NB. This evidence concerns the gene MYCN and neuroblastoma.